Literature DB >> 22037378

Comprehensive analysis of kinase inhibitor selectivity.

Mindy I Davis1, Jeremy P Hunt, Sanna Herrgard, Pietro Ciceri, Lisa M Wodicka, Gabriel Pallares, Michael Hocker, Daniel K Treiber, Patrick P Zarrinkar.   

Abstract

We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome. Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend. The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compounds tested. Analysis of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily. The data set suggests compounds to use as tools to study kinases for which no dedicated inhibitors exist. It also provides a foundation for further exploring kinase inhibitor biology and toxicity, as well as for studying the structural basis of the observed interaction patterns. Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037378     DOI: 10.1038/nbt.1990

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  29 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Functional interrogation of the kinome using nucleotide acyl phosphates.

Authors:  Matthew P Patricelli; A Katrin Szardenings; Marek Liyanage; Tyzoon K Nomanbhoy; Min Wu; Helge Weissig; Arwin Aban; Doris Chun; Stephen Tanner; John W Kozarich
Journal:  Biochemistry       Date:  2007-01-16       Impact factor: 3.162

3.  Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.

Authors:  Paul Bamborough; David Drewry; Gavin Harper; Gary K Smith; Klaus Schneider
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

4.  Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.

Authors:  Jeffrey R Simard; Matthäus Getlik; Christian Grütter; Ralf Schneider; Sabine Wulfert; Daniel Rauh
Journal:  J Am Chem Soc       Date:  2010-03-31       Impact factor: 15.419

5.  Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.

Authors:  Danzhi Huang; Ting Zhou; Karine Lafleur; Cristina Nevado; Amedeo Caflisch
Journal:  Bioinformatics       Date:  2009-11-26       Impact factor: 6.937

6.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

Authors:  Jeffrey F Ohren; Huifen Chen; Alexander Pavlovsky; Christopher Whitehead; Erli Zhang; Peter Kuffa; Chunhong Yan; Patrick McConnell; Cindy Spessard; Craig Banotai; W Thomas Mueller; Amy Delaney; Charles Omer; Judith Sebolt-Leopold; David T Dudley; Iris K Leung; Cathlin Flamme; Joseph Warmus; Michael Kaufman; Stephen Barrett; Haile Tecle; Charles A Hasemann
Journal:  Nat Struct Mol Biol       Date:  2004-11-14       Impact factor: 15.369

7.  Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Authors:  Xianming Deng; Nicolas Dzamko; Alan Prescott; Paul Davies; Qingsong Liu; Qingkai Yang; Jiing-Dwan Lee; Matthew P Patricelli; Tyzoon K Nomanbhoy; Dario R Alessi; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2011-03-06       Impact factor: 15.040

8.  Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors.

Authors:  Andrew J Olaharski; Nina Gonzaludo; Hans Bitter; David Goldstein; Stephan Kirchner; Hirdesh Uppal; Kyle Kolaja
Journal:  PLoS Comput Biol       Date:  2009-07-24       Impact factor: 4.475

Review 9.  Targeting the cancer kinome through polypharmacology.

Authors:  Zachary A Knight; Henry Lin; Kevan M Shokat
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

10.  Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.

Authors:  Francesca Carlomagno; Teresa Guida; Suresh Anaganti; Giancarlo Vecchio; Alfredo Fusco; Anderson J Ryan; Marc Billaud; Massimo Santoro
Journal:  Oncogene       Date:  2004-08-12       Impact factor: 9.867

View more
  619 in total

1.  Interrogating the kinome.

Authors:  Chao Zhang; Gaston Habets; Gideon Bollag
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

2.  The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding.

Authors:  Eduard R Felder; Alessandra Badari; Teresa Disingrini; Sergio Mantegani; Christian Orrenius; Nilla Avanzi; Antonella Isacchi; Barbara Salom
Journal:  Mol Divers       Date:  2012-02-15       Impact factor: 2.943

3.  The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

Authors:  M Skinner; K Philp; D Lengel; L Coverley; E Lamm Bergström; P Glaves; H Musgrove; H Prior; M Braddock; R Huby; J O Curwen; P Duffy; A R Harmer
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

4.  MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

Authors:  Lingtao Jin; Jaemoo Chun; Chaoyun Pan; Dan Li; Ruiting Lin; Gina N Alesi; Xu Wang; Hee-Bum Kang; Lina Song; Dongsheng Wang; Guojing Zhang; Jun Fan; Titus J Boggon; Lu Zhou; Jeanne Kowalski; Cheng-Kui Qu; Conor E Steuer; Georgia Z Chen; Nabil F Saba; Lawrence H Boise; Taofeek K Owonikoko; Fadlo R Khuri; Kelly R Magliocca; Dong M Shin; Sagar Lonial; Sumin Kang
Journal:  Cancer Cell       Date:  2018-07-19       Impact factor: 31.743

5.  Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets.

Authors:  Prson Gautam; Alok Jaiswal; Tero Aittokallio; Hassan Al-Ali; Krister Wennerberg
Journal:  Cell Chem Biol       Date:  2019-05-02       Impact factor: 8.116

6.  Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Authors:  Jihye Kim; Vihas T Vasu; Rangnath Mishra; Katherine R Singleton; Minjae Yoo; Sonia M Leach; Eveline Farias-Hesson; Robert J Mason; Jaewoo Kang; Preveen Ramamoorthy; Jeffrey A Kern; Lynn E Heasley; James H Finigan; Aik Choon Tan
Journal:  Bioinformatics       Date:  2014-05-07       Impact factor: 6.937

7.  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Authors:  Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard
Journal:  J Med Chem       Date:  2013-10-03       Impact factor: 7.446

8.  Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Authors:  Eric I Zimmerman; David C Turner; Jassada Buaboonnam; Shuiying Hu; Shelley Orwick; Michael S Roberts; Laura J Janke; Abhijit Ramachandran; Clinton F Stewart; Hiroto Inaba; Sharyn D Baker
Journal:  Blood       Date:  2013-09-17       Impact factor: 22.113

9.  Towards a RIOK2 chemical probe: cellular potency improvement of a selective 2-(acylamino)pyridine series.

Authors:  Christopher B Wang; Álvaro Lorente-Macías; Carrow Wells; Julie E Pickett; Alfredo Picado; William J Zuercher; Alison D Axtman
Journal:  RSC Med Chem       Date:  2020-11-11

10.  Expression of the essential Kinase PfCDPK1 from Plasmodium falciparum in Toxoplasma gondii facilitates the discovery of novel antimalarial drugs.

Authors:  Rajshekhar Y Gaji; Lisa Checkley; Michael L Reese; Michael T Ferdig; Gustavo Arrizabalaga
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.